Development of Emerging Modalities: Challenges and Strategies
The article outlines that emerging therapeutic modalities—such as antibody‑drug conjugates, multispecific antibodies, viral vectors, gene‑editing and RNA‑based medicines—present far greater molecular and manufacturing complexity than traditional biologics. Four primary hurdles are identified: structural heterogeneity, absence of universal platform processes, difficulty achieving high productivity, and regulatory uncertainty, all of which lengthen development timelines and raise costs. Industry leaders stress that specialized expertise, advanced analytics, and integrated CMC strategies are required to de‑risk projects and meet evolving regulator expectations. Financial pressure intensifies as investors now demand early clinical data and clear paths to scalable, cost‑effective manufacturing.
Massachusetts Hospital Turning Ambulances Away After Cyberattack
A cyberattack on Signature Healthcare Brockton Hospital in Massachusetts forced the facility to turn away ambulances and activate downtime procedures, cancelling chemotherapy infusions while keeping emergency rooms and surgeries operational. The hospital is working with external experts to restore systems,...
H.I.G.-backed Vernacare Scoops up Eakin Surgical
Vernacare, backed by private equity firm H.I.G., announced the acquisition of Eakin Surgical, a UK manufacturer of single‑use surgical instruments and procedure solutions. The deal adds a proven line of disposable tools to Vernacare’s existing portfolio, strengthening its foothold in...
Medicare Advantage Left 3 Million Seniors without a Plan, and Options Are Shrinking
Medicare Advantage enrollment, once a growing staple, saw a sharp reversal in 2026 as nearly 3 million seniors were forced to leave their plans. Disenrollment rates surged to 10% of beneficiaries, driven by insurers exiting counties due to rising medical costs...
Re: Increase in Remote Overseas Primary Care Consultations
A growing number of UK‑trained GPs are delivering primary‑care consultations from overseas locations, often in low‑tax jurisdictions such as Dubai. This trend raises questions about which regulatory body has authority over remote diagnoses, prescriptions, and liability. Critics argue that doctors...
ARPA-H Selects Three Teams in $100M Effort to Repair and Regrow Ailing Joints
ARPA-H announced a $100 million program to fund clinical trials for joint regeneration. Three leading academic centers were selected to test innovative therapies aimed at repairing and regrowing damaged cartilage and bone. The projects will explore senolytic drugs, engineered tissue scaffolds,...
Zimmer Hires Chief Science, Technology and Medical Affairs Officer
Zimmer Biomet announced the appointment of orthopedic surgeon Jonathan Vigdorchik as its chief science, technology and medical affairs officer, effective April 14. In his new role, Vigdorchik will oversee AI, robotics, smart implants, data analytics, and the company’s medical‑education strategy....
Gilead Continues M&A Surge with $3.1B Deal for ADC Specialist Tubulis
Gilead Sciences announced a deal to acquire German biotech Tubulis for $3.15 billion upfront, potentially rising to $5 billion with milestones. The purchase adds a next‑generation antibody‑drug conjugate (ADC) platform and two clinical candidates, TUB‑040 and TUB‑030, to Gilead’s oncology pipeline. This...
Terns Sold to Merck for 13% Lower than Pharma's Initial Offer because of Clinical Data
Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion, a price roughly 13% lower than its initial offer after new clinical data raised concerns. The renegotiated deal reflects the impact of late‑stage trial results on valuation in the biotech M&A wave....
Novo Launches High-Dose Wegovy in the US; Evotec Pressured to List Its US Unit
Novo Nordisk has introduced a high‑dose 7.2 mg version of its obesity drug Wegovy in the United States, expanding the GLP‑1 portfolio beyond the standard 2.4 mg dose. The new formulation targets patients with severe obesity who need greater weight‑loss efficacy. Pricing...
Houston Methodist to Deploy Midstream Health’s Agentic AI Financial Action Platform Across Enterprise
Houston Methodist has partnered with Midstream Health to roll out its Agentic AI Financial Action Platform across the health system, beginning with supply‑chain operations. The AI agents ingest both structured ERP data and unstructured contract PDFs to automatically detect pricing...
Robin Weiss Obituary
Robin Weiss, a pioneering virologist who died at 86, led the 1984 discovery that CD4 is the cellular receptor for HIV and created the first UK HIV antibody test with Richard Tedder. The test enabled large‑scale, accurate detection of HIV,...
Cooling Bracelet to Help Irish Women Battle Key Menopause Symptom
Irish engineer Aonghus O’Donovan has launched the MyCelsius cooling bracelet, a wrist‑worn device that drops skin temperature by 10 °C in under ten seconds. The wearable, entering the Irish market on April 7, targets menopausal hot flushes and claims an 80% efficacy...
Migraines Could Be Treated by Ramping up the Brain's Cleaning System
Researchers demonstrated that enhancing the brain's glymphatic waste‑clearance system can remove a migraine‑triggering chemical in mice, reducing facial pain symptoms. The approach repurposes a hypertension drug to boost clearance, offering a potential therapy for the one‑third of migraine sufferers who...
Sector Tariff Now More than a Threat – for some Rx Companies
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 blockers that demonstrate potent pre‑clinical analgesic activity for chronic neuropathic pain. New research links chronic inflammatory signaling to early leukemic transformation in hematopoietic stem cells, suggesting anti‑inflammatory approaches could intervene before disease...
Biopharma Financings Nearly Double Vs. 2025 to $25.1B
Biopharma financing in 2026 surged to $25.1 billion, almost twice the amount raised in 2025. The jump reflects a wave of venture‑capital commitments, a robust IPO market, and heightened merger‑and‑acquisition activity. Public offerings alone added roughly $8 billion, while private rounds supplied...
STAT+: Many Cancer Patients Don’t Get Genomic Tests to Guide Treatment, Study Finds
Genomic sequencing, a key component of precision oncology, is underused in metastatic cancer care. A JAMA Network Open study of five cancer types found that only about half of patients received tumor genetic testing, with lower rates among low‑income, Medicare/Medicaid,...
Five-Drug VIPOR Regimen Shows Promise in Aggressive Blood Cancer
Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that alleviate pain in rodent models without cardiac or CNS effects, and plan IND‑enabling toxicology studies in 2026 with Phase I trials slated for 2027. Parallel advances in hematopoietic...
Hematopoietic Stem Cell Research Points to Leukemia’s Early Roots
Recent hematopoietic stem cell (HSC) studies reveal that chronic inflammation can seed the earliest genetic lesions that later evolve into leukemia. The research shows that inflammatory signals remodel the bone‑marrow niche, prompting mutations in primitive stem cells long before clinical...
J&J Launches Enhanced PFA Device in Europe
Johnson & Johnson received CE‑mark approval for its Varipulse Pro pulsed‑field ablation (PFA) device and is launching it across Europe. The upgraded system delivers lesions five times faster than the prior sequence while maintaining comparable efficacy and operates at a lower...
Hong Kong Doctor Axed for Posting Resuscitation Photo Faces Medical Council Case
Hong Kong’s Hospital Authority terminated Dr. Jensen So’s contract after he posted an Instagram story showing a resuscitation procedure in a public ward. The authority said the doctor breached the professional code of conduct, lacked integrity and compromised patient privacy. The...
Gilead Outlays $5bn to Acquire ADC Specialist Tubulis
Gilead announced a deal to acquire German ADC specialist Tubulis for up to $5 bn, with $3.15 bn paid upfront and up to $1.85 bn in milestones. The transaction, slated to close in Q2 2026, brings Tubulis' lead candidate TUB‑040—a NaPi2b‑directed topoisomerase‑I inhibitor in...
FDA Clears Way for IDE Pivotal Trial of the Topaz Tricuspid Valve Replacement System
The U.S. Food and Drug Administration has granted an investigational device exemption (IDE) for TRiCares' Topaz transcatheter tricuspid valve replacement system, allowing a pivotal randomized trial across the United States, Canada, and Europe. The study will involve up to 75...
Wash. FD Becomes Test for University's Pre-Med Expansion
The University of Washington expanded its Health Care Alternative Spring Break program to include pre‑med students shadowing emergency medical services at Longview Fire Department. In 2024, 82% of the department’s calls were medical, underscoring the relevance of pre‑hospital experience. Students...
These Healthcare Stocks Offer Value and Rapid Profit Growth
Healthcare stocks are gaining momentum as the Centers for Medicare & Medicaid Services signaled higher Medicare Advantage payment rates for 2027. The prospect of increased reimbursements is boosting profit outlooks for managed‑care providers, with CVS Health rallying 4.5% after the...
Stop Waiting to Be Asked: What Operators Really Need From Their Revenue Cycle Partners
The article argues that healthcare revenue‑cycle partners must shift from reactive "tell us what you need" approaches to proactive, anticipatory support. Operators juggling access, staffing, patient experience, and finances often lack the bandwidth to articulate needs during crises. By identifying...
HexemBio Raises $10.4M Seed for Stem Cell Rejuvenation
HexemBio announced a $10.4 million seed round, led by Draper Associates with participation from SOSV, Seraphim and other investors. The biotech is developing a Synthetic Human Yolk Sac that temporarily houses a patient’s blood stem cells to rejuvenate their function before...
Insurers Committed to Cutting Prior Authorizations Have Eliminated 11% so Far
Major insurers have trimmed 11% of prior authorizations, eliminating roughly 6.5 million requests for U.S. patients, according to AHIP and the Blue Cross Blue Shield Association. The reduction is most pronounced in Medicare Advantage, where cuts exceed 15%. Insurers also report...
A Common Antidepressant Shows Promise in Treating Methamphetamine Dependence
A new JAMA Psychiatry study shows the antidepressant mirtazapine can modestly reduce methamphetamine use. In the double‑blind Tina Trial, 339 Australian participants received either 30 mg daily mirtazapine or placebo for 12 weeks. Those on mirtazapine cut meth use by an...
PharmaForce Appoints Industry Leader Lynn Eschenbacher to Lead Next Phase of 340B Strategy and Execution
PharmaForce has named Lynn Eschenbacher, PharmD, MBA, FASHP, as its new Chief Pharmacy and Strategy Officer to steer the company’s 340B program strategy. Eschenbacher brings over 25 years of pharmacy leadership across major health systems, most recently at Quva Pharma. The...
How Tech-Enabled Independent Pharmacies Can Address America’s Medication Adherence Crisis
Medication non‑adherence still costs U.S. drug makers roughly $250 billion a year, despite billions spent on marketing. Independent pharmacies, which patients visit nearly twice as often as primary‑care doctors, are emerging as a critical touchpoint as chain stores close. New pharmacy‑focused...
The Price Americans Pay for Medicine Has Gotten Horribly Out of Control. Here’s How to Fix It.
Humira, AbbVie’s adalimumab used by over 300,000 Americans, continues to dominate the market even after its patent expired, keeping prices sky‑high. The drug’s outsized share illustrates systemic flaws in U.S. pharmaceutical distribution, where limited biosimilar competition and opaque pricing inflate...
Ambulances Diverted After Cyberattack Hits Mass. Hospital
Brockton Hospital in Massachusetts is diverting ambulances and cancelling certain services after a cybersecurity incident disrupted its information systems. Chemotherapy infusions and retail pharmacies were suspended, while inpatient and walk‑in emergency care remain operational. The hospital reverted to paper records...
Maven Clinic Partners with Wellthy to Offer Integrated Family Care Benefits for Employers
Maven Clinic has teamed up with caregiving platform Wellthy to deliver an integrated family‑care benefit for employers. The joint solution merges Maven’s virtual women’s and family health services with Wellthy’s care‑coordination and backup‑care logistics, targeting the “sandwich generation” of workers...
STAT+: Pharmalittle: We’re Reading About FDA Backing Domestic Production, Another Gilead Deal, and More
The FDA, leveraging the Trump administration’s budget, unveiled proposals to boost domestic drug development and manufacturing, including streamlined early‑stage trials and a rule letting U.S. generic makers challenge brand patents a month before foreign competitors. Commissioner Marty Makary framed the...
Key Biosimilars Events of March 2026
March 2026 saw a surge of biosimilar activity, highlighted by Celltrion’s launch of Remsima IV in the EU and Avtozma SC in the United States, expanding both IV and sub‑cutaneous options for infliximab and tocilizumab. Samsung Bioepis inked a global...
FDA-Approved Drug Manufacturing Deals Shift to Europe
In 2025, U.S. contract manufacturing deals for FDA‑approved drugs fell sharply, while Europe recorded more than three times the U.S. volume. Despite a 15% U.S. tariff on EU pharmaceuticals, major U.S. firms such as Johnson & Johnson and Vertex invested...
Devex CheckUp: Trump Asks to Eliminate Billions for Global Health — Again
The White House’s FY 2027 budget request allocates $5.1 billion to global health, a modest increase over the previous year but far below the $9.4 billion Congress approved for FY 2026. The proposal cuts funding for the World Health Organization, the Pan‑American Health Organization,...
Samsung Introduces Android Enterprise and Knox Manage to Galaxy XR for Healthcare Deployments
Samsung upgraded its Galaxy XR headset with Android Enterprise support and Samsung Knox Manage integration, aiming at healthcare deployments. The enhancements let hospital IT departments manage the headsets like smartphones, applying data policies, network configurations, and remote lock or wipe functions....
Women in Northern Ireland Welcome Introduction of Miscarriage Leave
Northern Ireland has passed legislation granting statutory miscarriage leave, allowing employees up to five days of paid time off after a miscarriage. The measure aligns the region with England and Wales, which introduced similar provisions last year. Employers will treat...
Women’s Health Is Central to the Future of Digital Health
Digital health tools have long suffered from gender bias because training data and clinical trials underrepresent women. The Consumer Technology Association (CTA) has introduced the first ANSI‑accredited women’s health standard, giving developers a concrete framework for inclusive design, testing, and...
HexemBio Raises $10.4M for a Stem Cell Rejuvenation Therapy
HexemBio announced a $10.4 million seed round led by Draper Associates to develop a blood‑stem‑cell rejuvenation therapy built on its Synthetic Human Yolk Sac platform. The technology temporarily places a patient’s own haematopoietic cells into a recreated embryonic niche, then returns...
Untitled
Medline (Nasdaq: MDLN) has launched Pick Pack Pro™, an automated fulfillment system at its Montgomery, N.Y., distribution center. The technology combines robotics, conveyor sortation and right‑size packaging to handle high‑volume, narrow‑catalog orders for health plan members. By optimizing order batching...
Deal Roundup: EQT Life Sciences Exits Tubulis to Gilead, Foresight Scores 4x Return Selling TES to Legrand
EQT Life Sciences has exited its minority stake in Tubulis, the German clinical‑stage biotech developing next‑generation antibody‑drug conjugates, selling the position to Gilead Sciences. The transaction adds a promising ADC platform to Gilead’s oncology portfolio. In a separate deal, private‑equity...
The Future of Cell & Gene Therapy: Key Trends to Watch
Cell and gene therapy is transitioning from ex vivo manufacturing toward in vivo delivery, driven by advances in vector engineering and lipid‑nanoparticle platforms. Major pharma players have launched billion‑dollar acquisitions to secure in vivo CAR‑T and RNA technologies, while the stem‑cell market is...
From Low Yields to High Efficiency: Modernizing Complex Biologics Manufacturing
WuXi Biologics hosted a webcast detailing an integrated platform that can boost yields of complex biologics up to six‑fold while cutting manufacturing costs by as much as 80%. The approach combines platform‑based media optimization, cell‑culture intensification via WuXiUI™, downstream capacity...
From PC to CPV: Preserving Process Knowledge Through Late‑Phase Tech Transfer
Catalent’s Danielle Wittenwyler, PhD, will host a webinar on preserving years of process characterization (PC) during late‑phase tech transfers. She outlines a structured, risk‑based methodology that translates sponsor‑generated PC into Catalent’s Madison facility while maintaining design‑space intent. The approach identifies...
Stipple Launches with $100M for Novel Oncology Targets
Stipple, a new biotech focused on oncology, announced a $100 million Series A financing round to pursue novel, historically undruggable cancer targets. The round was led by top‑tier venture firms and includes strategic commitments from several large pharmaceutical partners. Stipple’s founding team...
Acadia Pharmaceuticals Presents GPR88 Agonists
Researchers at Jiangsu and Shanghai Hengrui have patented Nav1.8 blockers that deliver strong analgesic effects while sparing off‑target channels, opening a new avenue for chronic pain therapy. Parallel studies reveal that chronic inflammation can reprogram hematopoietic stem cells, driving early...
Chengdu Kanghong Pharmaceutical Patents New Lipoprotein(a)-Lowering Agents
Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that relieve neuropathic and inflammatory pain in rodents without impairing motor function, with filings in China and the United States and IND‑enabling work slated for later this year....